reports
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
Coloplast A/S - Finanskalender 2025-26
Coloplast A/S - Finanskalender 2025-26 Venligst se vedlagte pdf. For yderligere information og kalenderinvitationer til kommende begivenheder, besøg venligst: Med venlig hilsen,Investor RelationsColoplast A/STel. 4911 1800 For yderligere information, kontakt venligst Investorer og analytikereAnders Lonning-SkovgaardKoncerndirektør, CFOTlf. 4911 1111 Kristine Husted MunkSenior Director, Investor RelationsTlf. 4911 1800 / 4911 3266E-mail: Simone Dyrby HelvindSenior Manager, Investor RelationsTlf. 4911 1800 / 4911 2981E-mail: Presse og medierPeter MønsterSr. Media Relations Manage...
Coloplast A/S - Financial Calendar 2025-26
Coloplast A/S - Financial Calendar 2025-26 Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: Kind regards,Investor RelationsColoplast A/STel. For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. Kristine Husted MunkSenior Director, Investor RelationsTel. / Email: Simone Dyrby HelvindSenior Manager, Investor RelationsTel. / Email: Press and mediaPeter MønsterSr. Media Relations ManagerTel. Email: AddressColoplast A/SHoltedam 1DK-3050 HumlebaekDenm...
- ABGSC Healthcare Research
- Philip Ekengren
- Sten Gustafsson
Elekta AB: 1 director
A director at Elekta AB maiden bought 9,000 shares at 50.150SEK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
- ABGSC Healthcare Research
- Philip Ekengren
- Sten Gustafsson
- ABGSC Healthcare Research
- Morten Larsen
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’
Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’ Den nye 5-årige strategi, Impact4, vil blive lanceret i dag på selskabets Capital Markets Day 2025. Strategien Impact4 sætter kunden i centrum og udstikker samtidig et ambitiøst mål for selskabet – at hjælpe 4 millioner mennesker på lang sigt. Med Impact4 fokuserer vi på fire strategiske prioriteter, der er afgørende for vores succes og værdiskabelse: ’Grow through innovative customer offerings’ ved at sætte standarden for sundhedspleje og ved at skabe et stærkt fokus på kunderne på tværs af alle vores forretningsområder.’Unl...
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4 The new 5-year strategy, Impact4, will be presented today at the company’s Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to help 4 million people in the long-term. With Impact4, we focus on four strategic priorities which are essential to our success and value creation: Grow through innovative customer offerings, by setting the standard of care and driving strong customer centricity across all our business areas.Unlock next level e...
Coloplast A/S - Announcement no. 07/2025 - Coloplast fremlægger nye fi...
Coloplast A/S - Announcement no. 07/2025 - Coloplast fremlægger nye finansielle forventninger frem mod 2030 I forbindelse med lanceringen af Coloplasts nye 5-årige strategi, Impact4, offentliggør virksomheden en ny finansiel ambition med en organisk omsætningsvækst på 7-8 % (5-årige CAGR) frem til regnskabsåret 2029/30, en vækst i absolut EBIT* på niveau med eller over omsætningsvæksten i perioden og et afkast af investeret kapital (ROIC) på mere end 20 % i regnskabsåret 2029/30. På sin Capital Markets Day den 2. september 2025 vil Coloplast præsentere en ny 5-årig strategi, Impact4. I fo...
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new fin...
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial ambition towards 2030 In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in line with or above revenue growth over the period and Return on Invested Capital (ROIC) of more than 20% in FY 2029/30. At its Capital Markets Day on 2 September 2025, Coloplast will present a new 5-year strategy, Impact4. In relation to the strategic update, Coloplast is providing a new long-te...
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Small Cap Research
- Karl Bokvist
- Nikola Kalanoski
- Simon Jönsson
CTT CTT SYSTEMS AB
PREV B PREVAS B
CATE CATENA AB
GENI GENERIC SWEDEN AB PUBL
DUST DUSTIN GROUP AB
EKTA B ELEKTA AB CLASS B
STEF B STENDOERREN FASTIGHETER AB CLASS B
BONEX BONESUPPORT HOLDING AB
HMS HMS NETWORKS AB
MIPS MIPS AB
BOOZT BOOZT AB
A2DRL9 SDIPTECH AB B
FRACTL FRACTAL GAMING GROUP AB
RUG RUGVISTA GROUP AB
PACT PROACT IT GROUP
SFAB SOLID FORSAKRINGSAKTIEBOLAG
NOLA B NOLATO AB
HEM HEMNET GROUP AB (PUBL)
SLP B SWEDISH LOGISTIC PROPERTY AB
ITECH I-TECH AB
VESTUM VESTUM AB
ACAST-SE ACAST
SECT.B-SE SECTRA
GREEN GREEN LANDSCAPING GROUP AB (PUBL)
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Morten Larsen
- ABGSC Healthcare Research
- Morten Larsen
Arjo AB: 1 director
A director at Arjo AB bought 100,000 shares at 33.660SEK and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.